Two patients with chronic myelogenous leukemia are described in whom thrombotic thrombocytopenic purpura (TTP) developed following treatment by interferon-α. In one of the patients, a lymphoblastic transformation was diagnosed concomitantly. Prompt institution of plasmapheresis, steroids and vincristine resulted in complete resolution. In the hitherto reported case of TTP complicating interferon-α treated chronic myelogenous leukemia, the course was fatal.

Keywords:
Chronic myelogenous leukemia, Interferon, Plasmapheresis, Thrombotic thrombocytopenic purpura
1.
Gordon LI, Kwaan HC: Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:140–147.
2.
Bennet CI, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan MC, Green D: Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Intern Med 1998;128:541–544.
3.
Rose M, Rowe JM, Eldor A: The changing course of thrombotic thrombocytopenic purpura. Blood Rev 1993;7:94–103.
4.
Shammas F, Meyer P, Heikkila R, Apeland T, Goransson L, Berland J, Kjellevold K: Thrombotic microangiopathy in a patient with chronic myelogenous leukemia on hydroxyurea. Acta Haematol 1997;97:184–186.
5.
Stratta P, Canavese C, Dogliani M, Thea A, Degani G, Mairone L, Vercellone A: Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia. Ren Fail 1993;15:559–561.
6.
Harvey M, Rosenfeld D, Davies D, Hall BM: Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence? Am J Hematol 1994;46:152–153.
7.
Schlaifer D, Dumazer P, Spenatto N, Mignon-Conte M, Brousset P, Lumbroso C, Cooper M, Muller C, Huguet F, Attal M, Laurent G, Pris J: Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol 1994;47:254–255.
8.
Honda K, Ando A, Endo M, Shimizu K, Higashihara M, Nitta K, Nihei H: Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. Am J Kidney Dis 1997;30:123–130.
9.
Ubara Y, Hara S, Takedatu H, Katori H, Yamada K, Yoshihara K, Matsushita Y, Yokoyama K, Takemoto F, Yamada A, Takagawa R, Endo Y, Hara M, Koida I, Kumada H: Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C. Nephron 1998;80:107–108.
10.
Aguiar RCT, Beitler B, Dorihiac-Llacer PE, Chamone DAF: Secondary chronic myelogenous leukemia: A diverse pathogenesis. Acta Haematol 1994;92:101–103.
11.
Moses J, Lichtman SM, Brody J, Wisch N, Moake J: Hairy cell leukemia in association with thrombotic thrombocytopenic purpura and factor VIII antibodies. Leuk Lymphoma 1996;22:351–354.
12.
Moake JL: Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 1997;34:83–89.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.